OverviewSuggest Edit

IDEAYA Biosciences (IDEAYA) is a developer of molecular therapies. It is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations; for enhancing immunotherapy response and immuno-oncology therapies targeting the tumour microenvironment.

TypePublic
Founded2015
HQSouth San Francisco, CA, US
Websiteideayabio.com

Latest Updates

Employees (est.) (May 2019)56
Job Openings12
Revenue (FY, 2020)$19.5 M
Share Price (Jun 2021)$20.1(-1%)
Cybersecurity ratingAMore

Key People/Management at IDEAYA Biosciences

Michael P. Dillon

Michael P. Dillon

Senior Vice President and Chief Scientific Officer, Head of Research
Timothy Shannon

Timothy Shannon

Chairman of the Board
Yujiro S. Hata

Yujiro S. Hata

President and Chief Executive Officer, Director
Terry Rosen

Terry Rosen

Director
Mark Lackner

Mark Lackner

Senior Vice President, Head of Biology and Translational Sciences
Garret Hampton

Garret Hampton

Director
Show more

IDEAYA Biosciences Office Locations

IDEAYA Biosciences has offices in South San Francisco and San Diego
South San Francisco, CA, US (HQ)
7000 Shoreline Ct #350
San Diego, CA, US
3033 Science Park Rd
Show all (2)

IDEAYA Biosciences Financials and Metrics

IDEAYA Biosciences Revenue

IDEAYA Biosciences's revenue was reported to be $19.54 m in FY, 2020
USD

Revenue (Q1, 2021)

7.2m

Net income (Q1, 2021)

(9.0m)

EBIT (Q1, 2021)

(9.1m)

Market capitalization (4-Jun-2021)

660.7m

Closing stock price (4-Jun-2021)

20.1

Cash (31-Mar-2021)

136.8m

EV

530.3m
IDEAYA Biosciences's current market capitalization is $660.7 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

19.5m

General and administrative expense

2.1m4.7m10.0m15.2m

R&D expense

112.4m31.7m34.3m39.7m

Operating expense total

114.4m36.4m44.3m54.9m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

7.2m

General and administrative expense

885.0k2.1m2.4m2.7m3.5m4.0m4.8m

R&D expense

5.2m8.0m8.9m8.9m9.0m8.6m11.6m

Operating expense total

6.1m10.1m11.2m11.6m12.5m12.6m16.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.0m20.5m34.1m72.0m

Accounts Receivable

1.9m

Prepaid Expenses

419.0k706.0k2.7m3.1m

Current Assets

13.6m90.7m101.7m288.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

35.3m88.1m38.8m35.5m147.5m136.8m

Accounts Receivable

2.9m

Prepaid Expenses

857.0k2.5m2.8m1.6m3.5m2.9m

Current Assets

79.9m122.6m112.2m89.5m174.0m308.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.9m)(34.3m)(42.0m)(34.5m)

Depreciation and Amortization

391.0k886.0k1.2m1.4m

Accounts Payable

254.0k322.0k(195.0k)225.0k

Cash From Operating Activities

(12.2m)(27.6m)(39.3m)55.5m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(5.7m)(9.6m)(20.2m)(31.2m)(12.0m)(24.4m)(9.0m)

Depreciation and Amortization

193.0k293.0k591.0k915.0k336.0k673.0k382.0k

Accounts Payable

221.0k242.0k(189.0k)(153.0k)(36.0k)191.0k260.0k

Cash From Operating Activities

(5.5m)(9.8m)(20.1m)(30.6m)(9.5m)(23.2m)(13.7m)
USDFY, 2017

Financial Leverage

-1.1 x
Show all financial metrics

IDEAYA Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

IDEAYA Biosciences Online and Social Media Presence

Embed Graph

IDEAYA Biosciences News and Updates

IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 2021 Jefferies...

IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial...

IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced IDEAYA's inaugural Synthetic Lethality...

IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Susan Kelley, M.D., to...

IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND)...

IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced today that it has been selected for addition to the NASDAQ...
Show more

IDEAYA Biosciences Frequently Asked Questions

  • When was IDEAYA Biosciences founded?

    IDEAYA Biosciences was founded in 2015.

  • Who are IDEAYA Biosciences key executives?

    IDEAYA Biosciences's key executives are Michael P. Dillon, Timothy Shannon and Yujiro S. Hata.

  • How many employees does IDEAYA Biosciences have?

    IDEAYA Biosciences has 56 employees.

  • What is IDEAYA Biosciences revenue?

    Latest IDEAYA Biosciences annual revenue is $19.5 m.

  • What is IDEAYA Biosciences revenue per employee?

    Latest IDEAYA Biosciences revenue per employee is $348.9 k.

  • Who are IDEAYA Biosciences competitors?

    Competitors of IDEAYA Biosciences include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Ethypharm.

  • Where is IDEAYA Biosciences headquarters?

    IDEAYA Biosciences headquarters is located at 7000 Shoreline Ct #350, South San Francisco.

  • Where are IDEAYA Biosciences offices?

    IDEAYA Biosciences has offices in South San Francisco and San Diego.

  • How many offices does IDEAYA Biosciences have?

    IDEAYA Biosciences has 2 offices.